Astellas Pharma Announces Collaboration With Mass General Brigham
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said that it has reached a strategic collaboration with Mass General Brigham that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise.
The company stated that the five-year collaboration will focus on oncology, rare disease, and cell and gene therapies.
Astellas noted that the collaboration will leverage Mass General Brigham's clinical and research expertise, and capabilities including clinical data and human-derived cell models.
For More Such Health News, visit rttnews.com
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.